The future of recombinant coagulation factors

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 5, 2003, Pages 922-930

  Saenko, E L ^a   Ananyeva, N M ^a   Shima, M ^b   Hauserj, C A E ^c   Pipe, S W ^d  

^a HOLLAND LABORATORY   (United States)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF LÜBECK   (Germany)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bioengineering; Hemophilia; Recombinant factor IX; Recombinant factor VIII; Replacement therapy

Indexed keywords

EID: 2542543315     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00196.x     Document Type: Review

References (78)

1. Brinkhous K. Clotting defect in hemophilia: Deficiency in a plasma factor required for platelet utilization. Proc Soc Exp Biol Medl 1947; 66: 117.
2. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165-74.
3. Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
4. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7.
5. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-42.
6. Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollinghead P, Wion KL, Delwart E, Tudden ham EGD, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-7
7. Monahan PE, White IIGC. Hemophilia gene therapy. Update Curr Opin Hematol 2002; 9: 430-6.
8. High K. Gene-based approaches to the treatment of hemophilia. AnnN Y Acad Sci 2002; 961: 63-4.
9. High KA. Gene transfer as an approach to treating hemophilia. Circ Res 2001; 88: 137-44.
10. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-72.
11. Chuah MK, VandenDriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995; 6: 1363-77.
12. Kaufman RJ, Pipe SW Can we improve on nature? 'Super molecules' of factor VIII. Haemophilia 1998; 4: 370-9.
13. Hironaka T, Furukawa K, Esmon PC, Fournel MA, Sawada S, Kato M, Minaga T, Kobata A. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992; 267: 8012-20.
14. Kumar HP, Hague C, Haley T, Starr CM, Besman MI, Lundblad RL, Baker D. Elucidation of N-linked oligosaccharide structures of recom binant human factor VIII using fluorophore-assisted carbohydrate electrophoresis. Biotechnol Appl Biochem 1996; 24: 207-16.
15. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (≫95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-42.
16. Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 1987; 105: 2665-74.
17. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, Immunological, and in vivo Functional Characterization of B-Domain-Deleted Factor VIII. Blood 1993; 81: 2925-35.
18. Sandberg H, Almstedt A, Brandt J, Castro VM, Gray E, Holmquist L, Lewin M, Oswaldsson U, Mikaelsson M, Jankowski MA, Bond M, Scoble HA. Structural and functional characterization of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 4-12.
19. Courier SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hema tol 2001; 38: 52-9.
20. Courier SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol 2001; 38: 44-51.
21. Plantier JL, Rodriguez MH, Enjolras N, Attali O, Negrier C. A factor VIII minigene comprising the truncated intron I of factor IX highly improves the in vitro production of factor VIII. Thromb Haemost 2001; 86: 596-603.
22. Kurachi S, Hitomi Y, FurukawaM, Kurachi K. Role of intron I in expression of the human factor IX gene. J Biol Chem 1995; 270: 5276-81.
23. Enjolras N, Rodriguez MH, Plantier JL, Maurice M, Attali O, Negrier C. The three in-frame ATG, clustered in the translation initiation sequence of human factor IX gene, are required for an optimal protein production. Thromb Haemost 1999; 82: 1264-9.
24. Hoeben RC, Fallaux FJ, Cramer SJ, van den Wollenberg DJ, van Ormondt H, Briet E, van der Eb AJ. Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region. Blood 1995; 85: 2447-54.
25. Dorner AJ, Wasley LC, Kaufman RJ. Increased synthesis of secreted proteins induces expression of glucose- regulated proteins in butyrate-treated Chinese hamster ovary cells. J Biol Chem 1989; 264: 20602-7.
26. Dorner AJ, Wasley LC, Kaufman RJ. Overexpression of GRP78 miti gates stress induction of glucose regulated proteins and blocks secretion of selective proteins in Chinese hamster ovary cells. EMBO J 1992; 11: 1563-71.
27. Dorner AJ, Wasley LC, Kaufman RJ. Protein dissociation from GRP78 and secretion are blocked by depletion of cellular ATP levels. Proc Natl Acad Sci USA 1990; 87: 7429-32.
28. Tagliavacca L, Wang Q, Kaufman RJ. ATP-dependent dissociation of non-disulfide-linked aggregates of coagulation factor VIII is a rate-limiting step for secretion. Biochemistry 2000; 39: 1973-81.
29. Marquette KA, Pittman DD, Kaufman RJ. A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells. J Biol Chem 1995; 270: 10297-303.
30. Swaroop M, Moussalli M, Pipe SW, Kaufman RJ. Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secre tion of coagulation factor VIII. J Biol Chem 1997; 272: 24121-4.
31. Pittman DD, Marquette KA, Kaufman RJ. Role of the B domain for factor VIII and factor Vexpression and function. Blood 1994; 84: 4214-25.
32. Oeri J, Matter M, Isenschmid H, Hauser F, Roller F. Angeborener mangel an faktor V (parahaemophilie) verbunden mit echter haemo-philie A bein zwei brudern. Med Probl Paediatr 1954; 1: 575.
33. Pipe SW, Morris JA, Shah J, Kaufman RJ. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 1998; 273: 8537-44.
34. Pipe SW, Miao H, Tendulkar R, Kaufman RJ. Asparagine-linked glycosylation sites within the B domain of coagulation factor VIII improve secretion efficiency. Blood 2001; 98: 705a(Abstract No. 2947).
35. Voorberg J, van Stempvoort G, Bos JM, Mertens K, van Mourik JA, Donath MJ. Enhanced thrombin sensitivity of a factor VHI-heparin cofactor II hybrid. J Biol Chem 1996; 271: 20985-8.
36. Amano K, Michnick DA, Moussalli M, Kaufman RJ. Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: implications for the APC resistance test. Thromb Haemost 1998; 79: 557-63.
37. Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor Villa-dependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem 1996; 271: 6027-32.
38. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor Villa. Proc Nad Acad Sci USA 1997; 94: 11851-6.
39. Lenting P, Neels JG, van den Berg BM, Clijsters PFM, Meijerman DWE, Pannekoek H, van Mourik JA, Mertens K, Zonneveld A-J. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 23734-9.
40. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem 1999; 274: 37685-92.
41. Turecek PL, Lenting PJ, van Mourik JA, Binder B, Mihaly J, Denis C, Wagner D, Dorner F, Schwarz HP. Low density lipoprotein receptor-related protein (LRP) mediates the clearance of factor VIII in vWf-deficient mice. Blood 1999; 94: 647a.
42. Neels JG, Horn IR, Van den Berg BMM, Pannekoek H, van Zonneveld A-J. Ligand-receptor interactions of the low density lipoprotein re ceptor-related protein, a multi-ligand endocytic receptor. Fibrinolysis Proteolysis 1998; 12: 219-40.
43. Neels JG, van den Berg BM, Mertens K, Pannekoek H, Zonneveld A-J, Lenting P. Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein. Blood 2000; 96: 3459-65.
44. Narita M, Rudolph AE, Miletich JP, Schwartz AL. The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coa gulation factor Xa in vivo. Blood 1998; 91: 555-60.
45. Kounnas MZ, Church FC, Argraves WS, Strickand DK. Cellular inter-nalization and degradtion of antithrombin III-thrombin, heparin cofac tor II-thrombin, and alphal-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem 1996; 271: 6523-9.
46. Warshawsky I, Broze GJ Jr, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 6664-8
47. Turecek PL, Schwarz HP, Binder BR. In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor. Blood 2000; 95: 3637-8.
48. Ananyeva N, Kouiavskaia D, Shima M, Saenko E. Catabolism of the coagulation factor VIII. Can we prolong lifetime of fVIII in circulation? Trends Cardiovasc Med 2001; 11: 252-7.
49. Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein. J Biol Chem 2001; 276: 11970-9.
50. Tuddenham EG, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, Kernoff PB. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 1982; 52: 259-67.
51. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VHI/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65: 253-9.
52. Over J, Sixma JJ, Bruine MH, Trieschnigg MC, Vlooswijk RA, Bieser-Visser NH, Bouma BN. Survival of 125iodine-labeled factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978; 62: 223-34.
53. Fijnvandraat K, Berntorp E, Ten Cate JW, Johnsson H, Peters M, Savidge G, Tengborn L, Spira J, Stahl C. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77: 298-302.
54. Neels JG, Bovenschen N, Zonneveld A-J, Lenting P. Interaction be tween factor VIII and LDL receptor-related protein. Trends Cardiovasc Med 2000; 10: 8-14.
55. Mann DM, Romm E, Migliorini M. Delineation of the glycosamino-glycan-binding site in the human inflammatory response protein lacto-ferrin. J Biol Chem 1994; 269: 23661-7.
56. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. Three-Dimentional structure of membrane-bound coa gulation factor VIII. modeling of the factor VIII heterodimer within a three-dimentional density map derived by electron crystallography. Blood 2002; 99: 1215-23.
57. Rodenburg KW, Kjoller L, Petersen HH, Andreasen PA. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. Biochem J 1998; 329: 55-63.
58. Howard GC, Yamaguchi Y, Mirsa UK, Gawdi G, Nelsen A, DeCamp DL, Pizzo SV Selective mutations in cloned and expressed a2-macro-globulin receptor binding fragment alter binding to either the a2-macroglobulin signaling receptor or the low density lipoprotein recep tor-related protein/a2-macroglobulin receptor. J Biol Chem 1996; 271: 14105-11.
59. Knauer MF, Kridel SJ, Hawley SB, Knauer DJ. The efficient catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism that requires both the LDL receptor-related protein and cell surface heparins. J Biol Chem 1997; 272: 29039-45.
60. Saenko EL, Ananyeva NM, Kouiavskaia DV, Khrenov AV, Anderson JA, Shima M, Qian J, Scott D, Haemophilia A. effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia 2002; 8: 1-11.
61. Koshihara K, Qian J, Lollar P, Hoyer LW. Immunoblot cross-reactivity of factor VIII inhibitors with porcine factor VIII. Blood 1995; 86: 2183-90.
62. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 2000; 95: 564-8.
63. Thompson AR, Cheng S-H. Characterization of factor IX defects in hemophilia B. In: Methods in Enzymology. Colowick, SP, Kaplan, NO, eds. San Diego: Acad Press, Inc. 1993
64. Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-50.
65. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expres sion, purification, and characterization of recombinant gamma-carboxy-lated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261: 9622-8.
66. Roth DA, Kessler CM, Pasi KJ, Rup B, Courier SG, Tubridy KL. Human recombinant factor IX. safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
67. Suttie JW. Mechanism of action of vitamin K. synthesis of gamma-carboxyglutamic acid. CRC Crit Rev Biochem PG 1980; 8: 191-223.
68. Fernlund P, Stenflo J. Beta-hydroxyaspartic acid in vitamin K-dependent proteins. J Biol Chem 1983; 258: 12509-12.
69. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 1982; 79: 6461-4.
70. Balland A, Faure T, Carvallo D, Cordier P, Ulrich P, de la Fournet BSH, Lecocq JP. Characterisation of two differently processed forms of human recombinant factor IX synthesised in CHO cells transformed with a polycistronic vector. Eur J Biochem 1988; 172: 565-72.
71. Harrison S, Adamson S, Bonam D, Brodeur S, Charlebois T, Clancy B, Costigan R, Drapeau D, Hamilton M, Hanley K, Kelley B, Knight A, Leonard M, McCarthy M, Oakes P, Sterl K, Switzer M, Walsh R, FosterW. The manufacturing process for recombinant factor IX. Semin Rematol 1998; 35: 4-10.
72. Bond M, Jankowski M, Patel H, Karnik S, Strang A, Xu B, Rouse J, Koza S, Letwin B, Steckert J, Amphlett G, Scoble H. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35: 11-7.
73. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
74. Agarwala KL, Kawabata S, Takao T, Murata H, Shimonishi Y, Nishi-mura H, Iwanaga S. Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169. Biochemistry 1994; 33: 5167-71.
75. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G, Schwartz BA. Pharmaco-kinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
76. Zheng B, Qiu XY, Tan M, Xing YN, Lo D, Xue JL, Qiu XF. Increment of hFIX expression with endogenous intron 1 in vitro. Cell Res 1997; 7: 21-9.
77. Rodriguez MH, Enjolras N, Plantier JL, Rea M, Leboeuf M, Uzan G, Bordet JC, Negrier C. Expression of coagulation factor IX in a hae matopoietic cell line. Thromb Haemost 2002; 87: 366-73.
78. Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther 1999; 10: 2091-107